As of 2025-10-29, the Intrinsic Value of Kalvista Pharmaceuticals Inc (KALV) is -10.13 USD. This KALV valuation is based on the model Peter Lynch Fair Value. With the current market price of 11.13 USD, the upside of Kalvista Pharmaceuticals Inc is -191.02%.
Based on its market price of 11.13 USD and our intrinsic valuation, Kalvista Pharmaceuticals Inc (KALV) is overvalued by 191.02%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -10.13 - -10.13 | -10.13 | -191.02% |
| P/E | (31.12) - (31.16) | (31.20) | -380.4% |
| DDM - Stable | (16.69) - (61.03) | (38.86) | -449.2% |
| DDM - Multi | (12.60) - (36.97) | (18.93) | -270.1% |
| Market Cap (mil) | 562.29 |
| Beta | 1.04 |
| Outstanding shares (mil) | 50.52 |
| Enterprise Value (mil) | 570.30 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.74% |
| Cost of Debt | 5.00% |
| WACC | 8.78% |